1. Academic Validation
  2. Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy

Advanced Design, Synthesis, and Evaluation of Highly Selective Wee1 Inhibitors: Enhancing Pharmacokinetics and Antitumor Efficacy

  • J Med Chem. 2024 Jun 27;67(12):9927-9949. doi: 10.1021/acs.jmedchem.3c02434.
Yong Wang 1 Chunyue Xu 1 Yiqing Jiang 1 Zhenlin Tu 1 Jingxue Yan 1 Leyi Guo 1 Chao Dong 1 Jiaqi Liu 1 Xiulong Yang 1 Ziyi Wang 2 Tao Lu 1 3 Jie Feng 1 Yadong Chen 1 3
Affiliations

Affiliations

  • 1 School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P.R. China.
  • 2 Schcool of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P.R. China.
  • 3 State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, P.R. China.
Abstract

Wee1 is a kinase that regulates cell cycle arrest in response to DNA damage. Wee1 inhibition is a potential strategy to suppress the growth of tumors with defective p53 or DNA repair pathways. However, the development of Wee1 inhibitors faces some challenges. AZD1775, the first-in-class Wee1 Inhibitor, has poor kinase selectivity and dose-limiting toxicity. Here, we report the discovery of 12h, a highly selective and potent Wee1 Inhibitor with a favorable pharmacokinetic profile. 12h showed strong antiproliferative effects against Lovo cells, a colorectal Cancer cell line, both in vitro and in vivo. Moreover, 12h showed a clean kinase profile and effectively induced cell Apoptosis. Our results suggest that 12h is a promising drug candidate for further development as a novel Anticancer agent.

Figures
Products